LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Condition: Non-Small Cell Lung Cancer

Sponsor: NovoCure GmbH

Full Title
EF-44: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Study Treatment
1:1 randomization between treatment with standard of care chemo and immunotherapy +/- the addition of a Tumor Treatment Fields device.

Eligibility/Info

• Stage IV squamous or non-squamous non-small cell lung cancer
• No history of systemic therapy for advanced or metastatic non-small cell lung cancer
• No targetable oncogenic driver mutations

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage